A pharmaceutical formulation which is free of a phosphate buffer and selected from the group consisting of: (a) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of aggregated species of Adalimumab after storage at 5°C for 3 to 6 months of less than 5 %; (b) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of aggregated species of Adalimumab after storage at 25°C for 3 to 6 months of less than 5 %; (c) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of acidic species of Adalimumab after storage at 25°C for 3 to 6 months of less than 40 %; (d) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of aggregated species of Adalimumab under heat stress conditions for 10 minutes at 55°C of less than 5 %; (e) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of acidic species of Adalimumab under heat stress conditions for 10 minutes at 55°C of less than 40%; and (f) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffer solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and retaining TNFα neutralizing activity of at least 80% after storage of 6 months at a temperature of 5°C or 25°C, and/or after being subjected to heat stress for 10 minutes at 55°C, freeze-thaw conditions at -20°C to 5°C and/or mechanical stress; wherein the concentration of Adalimumab in the pharmaceutical formulation of any one of (a) to (f) is 50 mg/mL and the formulation further comprises a polyol and a surfactant which is a polysorbate, and wherein the aggregated species are measured by Size Exclusion High Performance Liquid Chromatography (HP-SEC) and the acidic species are measured by Strong Cation Exchange High Performance Liquid Chromatography (SCX-HPLC). (a) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of aggregated species of Adalimumab after storage at 5°C for 3 to 6 months of less than 5 %; (b) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of aggregated species of Adalimumab after storage at 25°C for 3 to 6 months of less than 5 %; (c) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of acidic species of Adalimumab after storage at 25°C for 3 to 6 months of less than 40 %; (d) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of aggregated species of Adalimumab under heat stress conditions for 10 minutes at 55°C of less than 5 %; (e) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffered solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and having a content of acidic species of Adalimumab under heat stress conditions for 10 minutes at 55°C of less than 40%; and (f) a liquid aqueous pharmaceutical formulation comprising a therapeutically effective amount of Adalimumab in a buffer solution comprising L-Histidine and citrate, said formulation having a pH of 5 to 5.5 and retaining TNFα neutralizing activity of at least 80% after storage of 6 months at a temperature of 5°C or 25°C, and/or after being subjected to heat stress for 10 minutes at 55°C, freeze-thaw conditions at -20°C to 5°C and/or mechanical stress;